Nonsteroidal aromatase inhibitors: Recent advances

被引:100
|
作者
Recanatini, M [1 ]
Cavalli, A [1 ]
Valenti, P [1 ]
机构
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
关键词
cytochrome P450; enzyme inhibitors; breast cancer therapy; anti-tumor drugs; steroid hormones;
D O I
10.1002/med.10010
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aromatase is the cytochrome P450 enzyme responsible for the last step of estrogen biosynthesis, and aromatase inhibitors constitute an important class of drugs in clinical use for the treatment of breast cancer. Nonsteroidal aromatase inhibitors (NSAIs) are competitive inhibitors of aromatase, which bind to the enzyme active site by coordinating the iron atom present in the heme group of the P450 protein. Presently, third generation NSAIs are in use, and research efforts are being carried out both to identify new molecules of therapeutic interest and to clarify the mechanism of action. In this article, we present a survey of the compounds that have been recently reported as NSAIs. to provide a broad view on the general structure-activity relationships of the class. Moreover, starting from the current knowledge of the mechanistic aspects of aromatase action and from recent theoretical work on the molecular modeling of both enzyme and inhibitors, we try to indicate a way to integrate these different studies in view of a more general understanding of the aromeatase-inhibitor system. Finally, some aspects regarding the possible future development of the field are considered briefly. (C) 2002 Wiley Periodicals, Inc.
引用
收藏
页码:282 / 304
页数:23
相关论文
共 50 条
  • [31] Aromatase and aromatase inhibitors
    Masakazu Toi
    Hiroko Bando
    Shigehira Saji
    Breast Cancer, 2001, 8 (4) : 329 - 332
  • [32] Switching from nonsteroidal aromatase inhibitors to exemestane and its impact on menopausal symptoms.
    Blanter, Julia
    Ezratty, Charlotte
    McIntyre, Anahi
    Sheng, Tianxiang
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future
    Aapro, Matti
    ANTI-CANCER DRUGS, 2008, 19 : S1 - S1
  • [34] SUBSTITUTED PYRIDINES - NONSTEROIDAL INHIBITORS OF HUMAN PLACENTAL AROMATASE CYTOCHROME-P-450
    VAZ, ADN
    COON, MJ
    PEEGEL, H
    MENON, KMJ
    DRUG METABOLISM AND DISPOSITION, 1992, 20 (01) : 108 - 112
  • [35] Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
    Goss, Paul E.
    Hadji, Peyman
    Subar, Milayna
    Abreu, Paula
    Thomsen, Torben
    Banke-Bochita, Jose
    BREAST CANCER RESEARCH, 2007, 9 (04)
  • [36] SUBSTITUTED BENZOCYCLOALKENES - STRUCTURE-ACTIVITY STUDIES IN A NEW CLASS OF NONSTEROIDAL INHIBITORS OF AROMATASE
    BARTZ, U
    WACHTER, G
    BAYER, H
    BATZL, C
    HARTMANN, RW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 36 - MEDI
  • [37] Development of steroidal and nonsteroidal inhibitors of aromatase for the treatment of hormone-dependent breast cancer
    OReilly, JM
    Brueggemeier, RW
    CURRENT MEDICINAL CHEMISTRY, 1996, 3 (01) : 11 - 22
  • [38] Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
    Paul E Goss
    Peyman Hadji
    Milayna Subar
    Paula Abreu
    Torben Thomsen
    Jose Banke-Bochita
    Breast Cancer Research, 9
  • [39] Recent advances in computational design of potent aromatase inhibitors: open-eye on endocrine-resistant breast cancers
    Spinello, Angelo
    Ritacco, Ida
    Magistrato, Alessandra
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (10) : 1065 - 1076
  • [40] Recent advances in the development of elastase inhibitors
    Donarska, Beata
    Laczkowski, Krzysztof Z.
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (20) : 1809 - 1813